CTOs on the Move

Nuvalent

www.nuvalent.com

 
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nuvalent.com
  • One Broadway 14th Floor
    Cambridge, MA USA 02142
  • Phone: 857.357.7000

Executives

Name Title Contact Details
Benjamin Lane
Senior Vice President of Technical Operations Profile

Funding

Nuvalent raised $135M on 05/11/2021

Similar Companies

Neurotech Pharmaceuticals

Neurotech Pharmaceuticals, Inc. is a Lincoln, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ECHO

Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.

Potenza Therapeutics

Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.